Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Vismodegib
État du projet:
Terminé
Domaine thérapeutique:
Basal Cell Carcinoma
Fabricant:
Hoffmann-La Roche Limited
Brand Name:
Erivedge
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0015-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
150 mg capsule
Tumour Type:
Peau et mélanome
Indications:
Advanced Basal Cell Carcinoma
Funding Request:
For the treatment of adult patients with histologically confirmed metastatic basal cell carcinoma or with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Demandée et accordée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016